Daniel Dahlberg

Mr. Daniel Dahlberg


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
DDDaniel Dahlberg
Daniel Dahlberg
JRJutta Rummel
Jutta Rummel
SDSonia Distante
Sonia Distante
GSGustavo Antonio De Souza
Gustavo Antonio De Souza
MSMaria Ekman Stensland
Maria Ekman Stensland
BHBjørnar Hassel
Bjørnar Hassel
Background: The growth of malignant tumors is influenced by their microenvironment. Glioblastoma, an aggressive primary brain tumor, may have cysts containing fluid that represents the tumor microenvironment. The aim of this study was to investigate whether the cyst fluid of cystic glioblastomas contains growth-stimulating factors. Identification of such growth factors may pave the way for the development of targeted anti-glioblastoma therapies. Methods: We performed hormone analysis of cyst fluid from 25 cystic glioblastomas and proteomics analysis of cyst fluid from another 12 cystic glioblastomas. Results: Glioblastoma cyst fluid contained hormones within wide concentration ranges: Insulin-like growth factor 1 (0–13.7 nmol/L), insulin (1.4–133 pmol/L), erythropoietin (4.7–402 IU/L), growth hormone (0–0.93 µg/L), testosterone (0.2–10.1 nmol/L), estradiol (0–1.0 nmol/L), triiodothyronine (1.0–11.5). Tumor volume correlated with cyst fluid concentrations of growth hormone and testosterone. Survival correlated inversely with cyst fluid concentration of erythropoietin. Several hormones were present at concentrations that have been shown to stimulate glioblastoma growth in vitro. Concentrations of erythropoietin and estradiol (in men) were higher in cyst fluid than in serum, suggesting formation by tumor or brain tissue. Quantitatively, glioblastoma cyst fluid was dominated by serum proteins, illustrating blood–brain barrier leakage. Proteomics identified several proteins that stimulate tumor cell proliferation and invasiveness, others that inhibit apoptosis or mediate adaption to hypoxia and some that induce neovascularization or blood–brain barrier leakage. Conclusion: The microenvironment of glioblastomas is rich in growth-stimulating factors that may originate from the circulation, the tumor, or the brain. The wide variation in cyst fluid hormone concentrations may differentially influence tumor growth.

17 September 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MAMerisa Abusdal
Merisa Abusdal
KNKjersti R Normann
Kjersti R Normann
TNTuula Anneli Nyman
Tuula Anneli Nyman
KØKristin Astrid Øystese
Kristin Astrid Øystese
ASArvind Y.M. Sundaram
Arvind Y.M. Sundaram
NONicoleta C Olarescu
Nicoleta C Olarescu
Purpose Silent corticotroph adenoma (SCA) exhibits more tumor aggressiveness features than functioning adenomas (FCA). We aimed to investigate PCSK1N expression in CA and examine if ER stress-induced responses affect cell survival in a corticotroph tumor cell model. Methods Clinical and imaging characteristics were recorded in 33 patients with FCA (20 women, 11 macroadenomas) and 18 SCA (8 women, all macroadenomas). Gene expression of proopiomelanocortin (POMC), T-box transcription factor 19(TBX19)/TPIT, proprotein convertase subtilisin/kexin type 1(PCSK1)/PC1/3, and its inhibitor PCSK1N, was measured by RT-qPCR in adenoma tissue. Mouse pituitary corticotroph tumor (AtT-20) cells were treated with tanespimycin (17-AAG), a HSP90 chaperone inhibitor, to induce ER stress, followed by gene and protein analyses. Results POMC, TPIT, and PCSK1 expression were higher, whereas PCSK1N was lower in FCA compared to SCA. PCSK1N correlated with POMC (rs= -0.514, p <0.001), TPIT (rs= -0.386, p = 0.005), PCSK1 (rs= -0.3691, p = 0.008), and tumor largest diameter (rs= 0.645, p <0.001), in all CA. Induction of ER stress by 17-AAG in AtT-20 cells led to a decrease of POMC and an increase of PCSK1N gene expression at 24h. Moreover, a downregulation of cell cycle, apoptosis, and senescence pathways, and alterations in cell adhesion and cytoskeleton were observed at the protein level. Conclusions PCSK1N is higher in SCA compared with FCA, and associated with corticotroph cell markers and tumor size. PCSK1N is likely to be part of the adaptive response to ER stress, potentially conferring a survival advantage to the corticotroph tumor cell in conjunction with other proteins.

5 March 2021 in Acta Neurochirurgica
Verified
Journal Article
Open access
PDF file
MWMarkus Wiedmann
Markus Wiedmann
ALAslan Lashkarivand
Aslan Lashkarivand
JBJon Berg-Johnsen
Jon Berg-Johnsen
DDDaniel Dahlberg
Daniel Dahlberg
Background: Tuberculum sellae meningiomas (TSMs) adherent to neurovascular structures are particularly challenging lesions requiring delicate and precise microneurosurgery. There is an ongoing debate about the optimal surgical approach. Method: We describe technical nuances and challenges in TSM resection using the endoscopic endonasal approach (EEA) in two cases of fibrous tumors with adherence to neurovascular structures. The cases are illustrated with a video (case 1) and figures (cases 1 and 2). Conclusion: A dedicated team approach and precise microsurgical technique facilitate safe resection of complex TSMs through the EEA.

28 March 2025 in Acta Neurochirurgica
Verified
Journal Article
Open access
PDF file
IOIda Olesrud
Ida Olesrud
IHIngeborg Janshaug Halvorsen
Ingeborg Janshaug Halvorsen
MSMarit Aarvaag Storaker
Marit Aarvaag Storaker
AHAnsgar Heck
Ansgar Heck
DDDaniel Dahlberg
Daniel Dahlberg
MWMarkus K. H. Wiedmann
Markus K. H. Wiedmann
Background: Over the last decade, endoscope integrated indocyanine green (E-ICG) fluorescence has been introduced in endoscopic skull base surgery. E-ICG seems to be a promising tool for intraoperative tissue differentiation, distinguishing pituitary neuroendocrine tumors (PitNET) from pituitary gland. More recent technical advancements have made E-ICG with simultaneous near-infrared/white-light overlay imaging available. E-ICG may improve intraoperative tumor identification, enabling more precise surgery and ultimately improved patient outcome. This systematic review evaluates the use of E-ICG for PitNET surgery. Methods: A systematic review was performed in accordance with PRISMA guidelines. PubMed, EMBASE, MedLine and Scopus databases were searched using different terms for “pituitary adenoma” combined with “Indocyanine green”. Data from relevant original papers were extracted and analyzed. Results: Fifteen studies were included in the final analysis. The studies employed different ICG administration and fluorescence assessment protocols. Endpoints and methodology were heterogenous. Study populations varied from one to 39 cases. A total of 193 patients underwent transsphenoidal endoscopic surgery with E-ICG for PitNET. ICG dosage varied from 5 mg to 25 mg/kg. Thirteen studies administered ICG intraoperatively. Eleven studies utilized first-generation endoscopes, requiring toggling between near infrared light fluorescence and white light. Second generation dual or overlay mode endoscopes were used in four studies. Tumor fluorescence was assessed in eleven studies (141 cases). Six studies utilized a quantitative method to assess ICG-fluorescence. Seven studies specifically reported surgical complications. No safety issues regarding ICG use were reported. Conclusions: The current literature is mainly based on small single center cohorts and case-studies, presenting a wide variety of approaches. Procedures and intraoperative assessment of fluorescence were mainly performed utilizing first-generation ICG endoscopes. There is lack of consensus in terms of ICG as an intraoperative tumor marker. Endoscopic ICG seems a promising tool for intraoperative real-time tissue differentiation, including vascular structures, tumor and pituitary gland.

11 April 2025 in Pituitary
Verified
Journal Article
Open access
PDF file
NONicoleta C. Olarescu
Nicoleta C. Olarescu
AJAnders Palmstrøm Jørgensen
Anders Palmstrøm Jørgensen
SAShahriar Atai
Shahriar Atai
MWMarkus K.H. Wiedmann
Markus K.H. Wiedmann
DDDaniel Dahlberg
Daniel Dahlberg
AHAnsgar Heck
Ansgar Heck
Background and purpose: In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance. Methods: We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology. Results: Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy. Conclusion: This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.

23 June 2026 in Brain and Spine
Verified
Journal Article
Open access
IOIda Olesrud
Ida Olesrud
MAMartin K. Andersen
Martin K. Andersen
CLChristopher Larsson
Christopher Larsson
AHAnsgar Heck
Ansgar Heck
DDDaniel Dahlberg
Daniel Dahlberg
MWMarkus K.H. Wiedmann
Markus K.H. Wiedmann
Intraoperative differentiation between pituitary adenoma (PA) and normal gland tissue remains a key challenge in endoscopic transsphenoidal surgery (ETSS). Indocyanine green fluorescence (ICG-FL) has been proposed as a visual adjunct. Existing data are limited and primarily based on first-generation systems requiring intermittent mode switching. Is implementation of a second-generation ICG endoscope with continuous white-light/near-infrared (WL/NIR) overlay safe and feasible in routine PA surgery? This prospective single-center observational study included consecutive patients undergoing ETSS for PA over a 28-month period. A second-generation ICG-FL endoscope with continuous WL/NIR overlay visualization was used throughout tumor resection. Primary endpoints were adverse events related to ICG-administration or device use. Secondary endpoints included surgical complications, short-term endocrine outcome and radiological residual tumor. After screening, 130 patients met inclusion criteria. Continuous WL/NIR overlay was successfully applied in all cases without intraoperative technical failure, dye-related adverse events, or need to revert to white-light-only visualization. Among functional PAs, 75% (52/69) achieved early biochemical remission. At follow-up, 22 patients (17%) had radiologically confirmed residual tumor, while 73 (56%) showed no residual disease. When combined with functional cases not undergoing MRI due to confirmed remission (n = 27), extrapolated gross-total resection was 77%. Continuous ICG-FL guidance was safe and feasible in routine ETSS for PA, without compromising surgical workflow, anatomical visualization, or requiring conversion to white-light-only endoscopy. Complication rates were consistent with contemporary endoscopic series. Continuous fluorescence provides real-time perfusion information that may facilitate improved tissue differentiation and warrants further comparative evaluation.